High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic LeukemiaPaul J. Hengeveld, Mark‐David Levin, Lina van der Straten et al.|Blood|2022Cited by 0